GRPH RSI Chart
Last 7 days
3.9%
Last 30 days
-7.7%
Last 90 days
-23.3%
Trailing 12 Months
-18.5%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 12, 2022 | samsara biocapital, l.p. | bought | 1,428,000 | 4.08 | 350,000 | - |
Apr 11, 2022 | gutry phil | bought | 20,050 | 4.01 | 5,000 | chief business officer |
Apr 11, 2022 | samsara biocapital, l.p. | bought | 303,068 | 4.07 | 74,464 | - |
Jan 24, 2022 | samsara biocapital, l.p. | bought | 200,100 | 8.7 | 23,000 | - |
Jan 21, 2022 | samsara biocapital, l.p. | bought | 899,000 | 8.99 | 100,000 | - |
Jan 20, 2022 | samsara biocapital, l.p. | bought | 384,497 | 8.92 | 43,105 | - |
Jan 19, 2022 | samsara biocapital, l.p. | bought | 504,181 | 9.24 | 54,565 | - |
Dec 15, 2021 | samsara biocapital, l.p. | bought | 227,533 | 10.19 | 22,329 | - |
Nov 22, 2021 | samsara biocapital, l.p. | bought | 2,047,100 | 10.15 | 201,685 | - |
Oct 15, 2021 | samsara biocapital, l.p. | bought | 28,727 | 12.49 | 2,300 | - |
Which funds bought or sold GRPH recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -84,341 | - | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | sold off | -100 | -12,086 | - | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | sold off | -100 | -343,398 | - | -% |
May 15, 2024 | Royal Bank of Canada | sold off | -100 | -20,000 | - | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | sold off | -100 | -74,770 | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -1,537,220 | - | -% |
May 15, 2024 | STATE STREET CORP | sold off | -100 | -1,138,300 | - | -% |
May 15, 2024 | MORGAN STANLEY | sold off | -100 | -536,520 | - | -% |
May 15, 2024 | JACOBS LEVY EQUITY MANAGEMENT, INC | sold off | -100 | -487,446 | - | -% |
May 15, 2024 | HSBC HOLDINGS PLC | sold off | -100 | -57,739 | - | -% |
Unveiling Graphite Bio, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Graphite Bio, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Graphite Bio, Inc. News
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | 208.8% | 217 | 70.00 | 266 | 287 | 310 | 47.00 | 335 | 354 | 379 | 402 | 416 | 387 | - |
Current Assets | 222.2% | 217 | 67.00 | 239 | 251 | 270 | 47.00 | 298 | 327 | 344 | 382 | 401 | 385 | 21.00 |
Cash Equivalents | 470.5% | 200 | 35.00 | 183 | 129 | 70.00 | 44.00 | 56.00 | 75.00 | 185 | 18.00 | 395 | 382 | 20.00 |
Net PPE | -9.3% | 0.00 | 0.00 | 13.00 | 18.00 | 33.00 | 0.00 | 13.00 | 10.00 | 9.00 | 7.00 | 6.00 | 2.00 | 1.00 |
Liabilities | -2.8% | 19.00 | 20.00 | 62.00 | 63.00 | 34.00 | 11.00 | 18.00 | 15.00 | 17.00 | 18.00 | 16.00 | 8.00 | 32.00 |
Current Liabilities | 2.0% | 19.00 | 19.00 | 13.00 | 12.00 | 14.00 | 9.00 | 14.00 | 12.00 | 13.00 | 12.00 | 11.00 | 8.00 | 32.00 |
Shareholder's Equity | 7.9% | 198 | 184 | 204 | 224 | 276 | 296 | 316 | 338 | 361 | 384 | 400 | 379 | - |
Retained Earnings | -17.5% | -111 | -95.20 | -344 | -321 | -266 | -25.28 | -217 | -193 | -167 | -141 | -122 | -107 | -70.59 |
Additional Paid-In Capital | 12218.7% | 310 | 3.00 | 548 | 546 | 543 | 1.00 | 536 | 533 | 529 | 525 | 523 | 487 | 5.00 |
Shares Outstanding | 161.8% | 26.00 | 10.00 | 8.00 | 8.00 | 8.00 | 10.00 | 8.00 | 8.00 | 8.00 | 8.00 | 3.00 | 1.00 | - |
Float | - | - | - | - | 151 | - | 66.00 | - | 150 | - | - | - | 817 | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | -47.3% | -23,937 | -16,250 | -9,401 | -13,655 | -21,074 | 61,460 | -22,217 | -22,094 | -21,240 | -15,593 | -15,415 | -13,784 | -8,060 | - | - | - |
Share Based Compensation | 113.7% | 947 | -6,926 | 2,161 | 2,845 | 3,263 | -9,191 | 3,210 | 3,360 | 3,342 | 2,446 | 2,374 | 2,018 | 1,033 | - | - | - |
Cashflow From Investing | 108.6% | 18,000 | -208,885 | 63,875 | 72,226 | 43,163 | 255,350 | 3,496 | -88,217 | -170,666 | -981 | -3,636 | -763 | -360 | - | - | - |
Cashflow From Financing | 112.6% | 171,268 | 80,576 | 8.00 | 124 | -8.00 | 29,909 | -59.00 | 412 | - | 313 | 31,890 | 219,497 | 165,767 | - | - | - |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |||
Operating expenses: | ||||
Research and development | $ 10,537 | $ 10,325 | ||
Selling, general and administrative | 5,551 | 2,291 | ||
Total operating expenses | 16,088 | 12,616 | ||
Loss from operations | (16,088) | (12,616) | ||
Other income (expense): | ||||
Other expense | (1,348) | (54) | ||
Interest income | 788 | 0 | ||
Total other income (expense), net | (560) | (54) | ||
Net loss | (16,648) | (12,670) | ||
Other comprehensive loss: | ||||
Unrealized loss on marketable securities | (7) | 0 | ||
Comprehensive loss | $ (16,655) | $ (12,670) | ||
Net loss per share attributable to common stockholders-basic | $ (3.53) | $ (6.50) | ||
Net loss per share attributable to common stockholders-diluted | $ (3.53) | $ (6.50) | ||
Weighted-average Class A common shares outstanding, basic (in shares) | [1] | 4,717,613 | 1,950,653 | |
Weighted-average Class A common shares outstanding, diluted (in shares) | [1] | 4,717,613 | 1,950,653 | |
|
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 | |||||
---|---|---|---|---|---|---|---|
Current assets: | |||||||
Cash and cash equivalents | $ 200,357 | $ 35,140 | |||||
Marketable securities | 12,922 | 30,654 | |||||
Prepaid expenses and other current assets | 3,281 | 1,450 | |||||
Restricted cash | 114 | 0 | |||||
Total current assets | 216,674 | 67,244 | |||||
Property and equipment, net | 49 | 54 | |||||
Operating lease right-of-use asset | 578 | 318 | |||||
Deferred offering costs | 0 | 2,739 | |||||
Security deposit | 21 | 21 | |||||
Total assets | 217,322 | 70,376 | |||||
Current liabilities: | |||||||
Accounts payable | 7,131 | 5,711 | |||||
Accrued liabilities | 11,757 | 12,803 | |||||
Total current liabilities | 18,888 | 18,514 | |||||
Operating lease liability, net | 156 | 192 | |||||
Other noncurrent liabilities | 111 | 121 | |||||
Preferred stock warrants liability | 0 | 871 | |||||
Total liabilities | 19,155 | 19,698 | |||||
Commitments and contingencies (Note 6) | |||||||
Convertible preferred and common stock: | |||||||
Total convertible preferred and common stock | 0 | 143,390 | |||||
Stockholders' deficit: | |||||||
Common stock, par value of $0.001 per share; 79,218,247 Class A shares authorized, and 9,915,013 shares issued at December 31, 2022 and 2023, respectively, and 9,629,171 and 9,739,818 shares outstanding at December 31, 2022 and 2023, respectively | [1] | 0 | 10 | ||||
Additional paid-in capital | [1] | 310,061 | 2,517 | ||||
Accumulated deficit | [1] | (111,893) | (95,245) | ||||
Accumulated other comprehensive income (loss) | [1] | (1) | 6 | ||||
Total stockholders’ equity (deficit) | 198,167 | (92,712) | [2] | ||||
Total liabilities, convertible preferred and common stock and stockholders’ equity (deficit) | 217,322 | 70,376 | |||||
Series A Convertible Preferred Stock | |||||||
Convertible preferred and common stock: | |||||||
Total convertible preferred and common stock | 0 | 44,621 | [2] | ||||
Series A-1 Convertible Preferred Stock | |||||||
Convertible preferred and common stock: | |||||||
Total convertible preferred and common stock | 0 | 9,893 | [2] | ||||
Series B Convertible Preferred Stock | |||||||
Convertible preferred and common stock: | |||||||
Total convertible preferred and common stock | 0 | 82,976 | |||||
Class B Convertible Common Stock | |||||||
Convertible preferred and common stock: | |||||||
Total convertible preferred and common stock | $ 0 | $ 5,900 | [2] | ||||
|